[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-401152-105":59,"doc-detail-401152-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cog-ltfu-guidelines-version-60-october-2023","COG LTFU Guidelines - Version 6.0 - October 2023","","Long-Term Follow-Up Guidelines for survivors of childhood, adolescent, and young adult cancers provide an organized reference linking cancer exposures and treatments to potential late effects. The material includes a structured overview by treatment category, such as any cancer experience, blood/serum products, chemotherapy, and radiation, with associated risks including psychosocial and mental health outcomes, endocrinopathies, organ toxicities, neurologic effects, infertility-related complications, and secondary malignancies. It is presented as a versioned guideline resource with introductory materials and an indexed contents section.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cog-ltfu-guidelines-version-60-october-2023/401152/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cog-ltfu-guidelines-version-60-october-2023/401152.png","ImageObject",300,407,{"name":92,"@type":93},"Đào","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-27",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What populations do these long-term follow-up guidelines cover?","Question",{"text":113,"@type":114},"Survivors of childhood, adolescent, and young adult cancers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How are potential late effects organized in the guideline contents?",{"text":118,"@type":114},"They are mapped by exposure and treatment category, such as any cancer experience, blood/serum products, chemotherapy, and radiation.",{"name":120,"@type":111,"acceptedAnswer":121},"What kinds of late effects are listed for chemotherapy and radiation?",{"text":122,"@type":114},"Examples shown include psychosocial and mental health effects, neurologic complications, endocrine deficiencies, organ toxicities (e.g., cardiac or pulmonary), and increased risks of secondary malignancies.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},401152,1790847264,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Long-Term Follow-Up Guidelines  \nfor Survivors of Childhood, Adolescent, and Young Adult Cancers  \nVersion 6.0-October 2023  \n[Website: www.survivorshipguidelines.org](Website: www.survivorshipguidelines.org)[ ](Website: www.survivorshipguidelines.org)Copyright 2023 © Children’s Oncology Group All rights reserved worldwide  \nLong-Term Follow-Up Guidelines  \nfor Survivors of Childhood, Adolescent, and Young Adult Cancers  \nVersion 6.0 – October 2023  \n[www.survivorshipguidelines.org](www.survivorshipguidelines.org)  \nCopyright 2023 © Children’s Oncology Group All rights reserved worldwide  \n\n| Generously supported by With special appreciation to |  |\n| --- | --- |\n| | Anna DeVine, RN, BSN, CPN, CPHON Oncology-Survivorship St. Jude Children’s Research Hospital for editing and typesetting |\n\nContents  \n\n| Introductory Materials | Page |\n| --- | --- |\n| Abstract | x |\n| Disclaimer and Notice of Proprietary Rights | xi |\n| Contributors-Panel of Experts | xii |\n| Contributors-Task Force Membership 2019-2023 | xv |\n| Contributors-Guideline Development Task Force-Initial Versions | xx |\n| Preface | xxi |\n| Instructions for Use | xxvi |\n| New to Version 6.0 | xxviii |\n| Abbreviations and parameters | xxxi |\n\n\n| Section \\# | Page | Sex | Therapeutic Agent | Potential Late Effect |\n| --- | --- | --- | --- | --- |\n| Any Cancer Experience |  |  |  |  |\n| 1 | 1 |  | Any Cancer Experience | Adverse psychosocial/quality of life effects |\n| 2 | 3 |  | Any Cancer Experience | Mental health disorders |\n| 3 | 4 |  | Any Cancer Experience | Risky behaviors |\n| 4 | 5 |  | Any Cancer Experience | Psychosocial disability due to pain |\n| 5 | 6 |  | Any Cancer Experience | Fatigue; Sleep problems |\n| 6 | 7 |  | Any Cancer Experience | Limitations in healthcare and insurance access |\n| 7 | 8 |  | Any Cancer Experience | Subsequent malignancy/Risk of malignancy in offspring |\n| Blood/Serum Products |  |  |  |  |\n| 8 | 9 |  | Diagnosed prior to 1972 | Chronic hepatitis B |\n| 9 | 10 |  | Diagnosed prior to 1993 | Chronic hepatitis C |\n| 10 | 11 |  | Diagnosed between 1977 and 1985 | HIV infection |\n| Chemotherapy |  |  |  |  |\n| 11 | 12 |  | Any Chemotherapy | Dental abnormalities |\n| 12 | 13 | Male | Alkylating Agents | Testicular hormonal dysfunction |\n\nCOG LTFU Guidelines – Page v  \n\n| Section \\# | Page | Sex | Therapeutic Agent | Potential Late Effect |\n| --- | --- | --- | --- | --- |\n| 13 | 14 | Male | Alkylating Agents | Impaired spermatogenesis |\n| 14 | 16 | Female | Alkylating Agents | Ovarian hormone deficiencies |\n| 15 | 18 | Female | Alkylating Agents | Diminished ovarian reserve (DOR) |\n| 16 | 20 |  | Alkylating Agents | Acute myeloid leukemia; Myelodysplasia |\n| 17 | 21 |  | Alkylating Agents | Pulmonary fibrosis |\n| 18 | 22 |  | Alkylating Agents | Cataracts |\n| 19 | 23 |  | Alkylating Agents | Urinary tract toxicity |\n| 20 | 24 |  | Alkylating Agents | Bladder malignancy |\n| 21 | 25 |  | Alkylating Agents | Renal toxicity |\n| 22 | 26 |  | Heavy Metals | Ototoxicity |\n| 23 | 28 |  | Heavy Metals | Peripheral sensory neuropathy |\n| 24 | 29 |  | Heavy Metals | Renal toxicity |\n| 25 | 30 |  | Antimetabolites | Neurocognitive deficits |\n| 26 | 31 |  | Antimetabolites | No known late effects (cytarabine [low dose IV, IO, IT, SQ]) |\n| 27 | 32 |  | Antimetabolites | Hepatic dysfunction; Sinusoidal obstruction syndrome (SOS) |\n| 28 | 33 |  | Antimetabolites | No known BMD late effects (methotrexate) |\n| 29 | 34 |  | Antimetabolites | No known renal late effects (methotrexate) |\n| 30 | 35 |  | Antimetabolites | Hepatic dysfunction |\n| 31 | 36 |  | Antimetabolites | Neurocognitive deficits |\n| 32 | 37 |  | Antimetabolites | Clinical leukoencephalopathy |\n| 33 | 38 |  | Anthracycline Antibiotics | Acute myeloid leukemia |\n| 34 | 39 |  | Anthracycline Antibiotics | Cardiac toxicity |\n| 35 | 41 |  | Anti-Tumor Antibiotics | Pulmonary toxicity |\n| 36 | 42 |  | Anti-Tumor Antibiotics | No known late effects (dactinomycin) |\n| 37 | 43 |  | Corticosteroids | ","cbCaibgahNAyNGHb","https://ap.wps.com/l/cbCaibgahNAyNGHb","pdf",2942740,391,"English","# Introductory Materials\n## Abstract\n## Disclaimer and Notice of Proprietary Rights\n## Contributors-Panel of Experts\n## Contributors-Task Force Membership 2019-2023\n## Contributors-Guideline Development Task Force-Initial Versions\n## Preface\n## Instructions for Use\n## New to Version 6.0\n## Abbreviations and parameters\n# Treatment- and Exposure-Based Late Effects Overview\n## Any Cancer Experience\n## Blood/Serum Products\n## Chemotherapy\n## Radiation","[{\"question\":\"What populations do these long-term follow-up guidelines cover?\",\"answer\":\"Survivors of childhood, adolescent, and young adult cancers.\"},{\"question\":\"How are potential late effects organized in the guideline contents?\",\"answer\":\"They are mapped by exposure and treatment category, such as any cancer experience, blood/serum products, chemotherapy, and radiation.\"},{\"question\":\"What kinds of late effects are listed for chemotherapy and radiation?\",\"answer\":\"Examples shown include psychosocial and mental health effects, neurologic complications, endocrine deficiencies, organ toxicities (e.g., cardiac or pulmonary), and increased risks of secondary malignancies.\"}]","COG LTFU Guidelines - Version 6.0 - October 2023 | PDF",1790517135,985]